Online Pharmacy Training

The U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

Clinical Context Tadalafil is a phosphodiesterase-5 (PDE5) inhibitor that was approved by the US Food and Drug Administration (FDA) in 2003 to treat erectile dysfunction (ED). The FDA has now expanded the approved indications to include benign prostatic hyperplasia (BPH), either alone or in combination with ED.